Vectibix (Panitumumab, manufactured by Amgen) hasn’t been on market for a full six months - and already it has encountered a setback. The manufacturer has recently stopped a late stage colon cancer clinical study after observing that Vectibix actually reduced the rate of survival in colon cancer patients compared with patients who received other drugs. Additionally, patients taking Vectibix had an increased risk of developing blood clots in the lung that can have fatal consequences (pulmonary embolism). Source: Reuters. Reuters go more into the financials of this setback than the science or medicine.
Latest Tips RSS
-
TargetingTumors.com
-
TargetingTumors.com
Vectibix or panitumumab is made by Amgen and has been approved by the US Food and Drug Administration (FDA) for treating advanced colorectal cancer in patients who have failed standard chemotherapy. Amgen has announced that Vectibix will be 20% cheaper than other antibody therapies on market and the company has created a financial assistance program called Amgen Oncology Assistance (AOA) that limits the out-of-pocket co-payments from cancer patients on Vectibix. The program will also be available to patients in need or who are uninsured. (More …)